Provided by Tiger Trade Technology Pte. Ltd.

Disc Medicine

60.09
-1.9200-3.10%
Post-market: 60.090.00000.00%16:58 EDT
Volume:318.20K
Turnover:19.26M
Market Cap:2.29B
PE:-10.00
High:62.34
Open:62.20
Low:60.00
Close:62.01
52wk High:99.50
52wk Low:30.82
Shares:38.16M
Float Shares:32.89M
Volume Ratio:0.41
T/O Rate:0.97%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.0116
EPS(LYR):-6.0116
ROE:-35.86%
ROA:-22.55%
PB:3.10
PE(LYR):-10.00

Loading ...

Disc Medicine Inc - on Feb 26, Board Approves Restructuring Plan - SEC Filing

THOMSON REUTERS
·
Feb 28

Disc Medicine Inc - Expects Charges of About $2 Mln to Be Recorded Primarily in Q1 2026 - SEC Filing

THOMSON REUTERS
·
Feb 28

Disc Medicine CFO Jean M. Franchi Disposes of Common Shares

Reuters
·
Feb 28

Disc Medicine to Cut Workforce by 20% in Restructuring Plan

Reuters
·
Feb 28

Disc Medicine Is Maintained at Buy by Truist Securities

Dow Jones
·
Feb 28

Truist Financial Keeps Their Buy Rating on Disc Medicine (IRON)

TIPRANKS
·
Feb 27

Disc Medicine Q4 EPS $(1.62) Beats $(1.68) Estimate

Benzinga
·
Feb 27

Disc Medicine Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Feb 26

Disc Medicine (IRON) FY 2025 net loss totals USD 212.2 million

Reuters
·
Feb 26

Disc Medicine FY Basic EPS USD -6.01 VS. Ibes Estimate USD -6.14

THOMSON REUTERS
·
Feb 26

Press Release: Disc Medicine Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Dow Jones
·
Feb 26

Disc Medicine to Participate in Upcoming Investor Conferences

GlobeNewswire
·
Feb 24

Disc Medicine (IRON) Receives a Buy from LifeSci Capital

TIPRANKS
·
Feb 21

Disc Medicine CFO Jean M. Franchi Disposes of Common Shares

Reuters
·
Feb 20

Chief Commercial Officer Pamela Stephenson Reports Disposal of Disc Medicine Inc. i Common Shares

Reuters
·
Feb 18

Disc Medicine CEO John D. Quisel Reports Sale of Common Shares

Reuters
·
Feb 18

Disc Medicine's Multiple Catalysts Provide Runway Despite Bitopertin Delay, Morgan Stanley Says

MT Newswires Live
·
Feb 18

Wedbush Adjusts Price Target on Disc Medicine to $88 From $110, Maintains Outperform Rating

MT Newswires Live
·
Feb 17

Disc Medicine Inc. i details bitopertin regulatory update and clinical trial progress

Reuters
·
Feb 17

Disc Medicine Is Maintained at Overweight by Wells Fargo

Dow Jones
·
Feb 17